Sai Life Sciences Limited has informed the Exchange regarding a press release dated January 28, 2026, titled "Strategic Collaboration Between Mabtech and Sai Life Sciences to Advance Immunology Research with EYRA Platform at Sai Boston Site.
SAILIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sai Life Sciences has shared a press release announcing a strategic collaboration with Mabtech, a Swedish life sciences company. The partnership will use Mabtech's EYRA Platform to advance immunology research, based out of Sai's Boston site. The collaboration focuses on strengthening research capabilities in immunology through the combined expertise of both companies. No financial terms, deal value, or equity involvement were disclosed in this announcement.
This is a research-focused partnership that could enhance Sai Life Sciences' credibility and capabilities in the immunology and contract research space, but it is unlikely to have a material short-term impact on stock price as no financial details or equity arrangements were shared.